Farletuzumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Farletuzumab
Monoclonal antibody
Type Whole antibody
Source Humanized
Target FR-alpha
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
Formula C6466H9928N1716O2020S42
Molar mass 145.4 kg/mol
 NYesY (what is this?)  (verify)

Farletuzumab (MORAb-003) is a monoclonal antibody[1] which is being investigated for the treatment of ovarian cancer.[2][3]

This drug was developed by Morphotek, Inc.

It is targeted at FR-alpha which is overexpressed in some cancers such as ovarian cancer.

References[edit]

  1. ^ Statement On A Nonproprietary Name Adopted By The Usan Council - Farletuzumab, American Medical Association.
  2. ^ ClinicalTrials.gov: Phase II Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer
  3. ^ ClinicalTrials.gov: Phase III Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse